2015 USTR Special 301 Report Reactions and the way forward
In the aftermath of this year’s USTR Special 301 Report, which retained India on the Priority Watch List, industry leaders comment…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
‘Special 301 Report annual swat at India’s IP policies’
In an exclusive analysis for Express Pharma, Professor Brook K Baker, Northeastern U School of Law, and senior policy analyst,…
‘First make improvements in government infrastructure that implement IPR laws’
Milind Antani, Partner in charge of pharma-life sciences and healthcare practice, Nishith Desai Associates, Ajay Chandru and…
Drug Price Rise An Efficacious Move?
National Pharmaceutical Pricing Authority (NPPA) has allowed pharma companies to increase the prices of 509 essential medicines in…
Possible effects of DE implementation in India
Sankar Sundaram, Professor of Pharmaceutical Sciences, JSS University, talks about data exclusivity and if effective then how it…
Melanoma treatment market value to more than quadruple to $5.64 bn by 2023: GlobalData
The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated…
‘Pharmerging’ markets: Dealing with uncertainty
Executives in the life sciences industry reveal their key concerns in cross-border acquisitions in pharmerging markets
Top mid-cap biotech firms’ total revenues increase to $26.5 bn in 2014: GlobalData
The company’s latest report states that this growth was marginally slower than during the previous five years
A Question of Trust
Though buying medicines online has become a convenience for the patients, the reliability and the authenticity of such online…
Global Type I diabetes treatment market value doubling to $13.6 billion by 2023: GlobalData
Across the eight major markets of the US, France, Germany, Italy, Spain, UK, Japan and Canada, growth will be driven primarily by…
Targeted therapies offer novel treatment modalities for breast cancer: Frost & Sullivan
The use of combination targeted therapies will improve progression-free disease as well as survival rates
Reorienting the innovation management process
In the search for growth, pharmaceutical companies often face harsh reality when new OTC launches flop because they did not match…
Impact of IT on Indian pharma industry
Dr Subroto Ghoshal, Manager- Human Resources, Mindteck India elaborates on the need to improve connectivity between IT and pharma…
Growth hormone therapy market favours biobetters over biosimilars
GlobalData analyst states that long-acting GH biobetters will have an increased chance of market uptake upon entry
Big Pharma drives innovation in pain therapy development, despite declining patent applications
Patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck…
Current status of clinical research in India
Dr YK Gupta, Professor and Head, Department of Pharmacology, AIIMS, New Delhi expounds on the measures taken to revive clinical…
Art and science of pharma marketing
Pawan Chaudhary, CMD, Venus Remedies, gives an overview on the evolution of pharma marketing and the need to 'think out of the…
Human insulin market will reach $49,197.3 million in 2020 globally: Persistence Market Research
Asia Pacific to show fast growth rates in the next five years
Budget 2015: Awaiting Achche Din
Industry experts share their expectations and wish-list from Budget 2015. FM Arun Jaitley's first Union Budget for heralding the…
Will a new US-led IP empire in India put access to medicines at risk?
Prof Brook K Baker, Professor of Law and Northeastern University, cautions that the Modi government’s accelerating flirtation with…